Introduction

The World Health Organization has announced a partnership with Singapore government-owned investment firm Temasek Holdings to develop what it describes as 'interoperable digital health wallets' for global use. The initiative builds on digital documentation systems used during the COVID-19 pandemic and follows recent amendments to the WHO’s International Health Regulations.

The partnership, announced earlier this week, will begin with a pilot program involving the 11 member states of the Association of Southeast Asian Nations (ASEAN). According to the WHO, the program aims to create a 'replicable model' for potential export to other countries. The digital wallets will initially contain digital international certificates of vaccination or prophylaxis, with plans to later expand to 'broader personal health summaries' ^[1][2][3].

WHO Announces Partnership for Global Digital Health Passports

The WHO stated the initiative 'builds on lessons from the COVID-19 pandemic, which demonstrated the urgency of reliable, verifiable digital health documentation' ^[2]. Kee Kirk Chuen, Temasek’s head of Health & Well-being, said the COVID-19 pandemic 'showed how important it is for health records to be trusted, verifiable and able to travel with people across borders' ^[2].

The pilot program in Southeast Asia is intended to serve as a test case for broader implementation. According to the WHO announcement, the system will use standards developed by the WHO Global Digital Health Certification Network (GDHCN), which was launched in partnership with the European Commission in 2023 ^[2]. The partnership follows 2024 amendments to the International Health Regulations (IHR) which recommended the development of 'globally recognized digital health certificates' ^[2].

Temasek's Pharmaceutical and Digital Health Investments

Temasek Holdings, owned by the Government of Singapore, has a substantial investment portfolio in pharmaceutical companies and digital health infrastructure. In June 2020, Temasek participated in a $250 million investment in BioNTech, a German biotechnology company, just months before BioNTech released a COVID-19 vaccine in conjunction with Pfizer ^[2][3]. A BioNTech press release at the time stated the investment would boost the company’s efforts to develop 'patient-specific immunotherapies for the treatment of cancer and infectious diseases' ^[2]